Core Viewpoint - The company has successfully registered a new product, a daily wear soft hydrophilic contact lens, which has received a Class III medical device registration certificate [1] Product Details - The new product is composed of HEMA, NVP, GMMA, EGDMA, and coloring agents, and is packaged in a light blue PP cup [1] - The lens has a nominal water content of 43% and is recommended for daily replacement [1] - The product undergoes moist heat sterilization and has a shelf life of 5 years [1] - It is intended for daily wear to correct myopia in patients without contraindications [1] - The registration certificate number is 国械注准20253162076, valid until October 20, 2030 [1]

Financial Performance - The company's revenue for Q3 2025 was ¥562,095,281.42, representing a 2.62% increase year-over-year[5] - The net profit attributable to shareholders for Q3 2025 was ¥192,052,456.69, a decrease of 3.10% compared to the same period last year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2025 was ¥175,553,233.68, down 7.70% year-over-year[5] - For the first three quarters of 2025, total revenue reached ¥1,432,791,310.58, a slight increase of 0.13% compared to the previous year[10] - The net profit attributable to shareholders for the first three quarters of 2025 was ¥442,049,628.72, reflecting a decline of 15.41% year-over-year[10] - Total revenue for the current period reached ¥1,432,791,310.58, slightly up from ¥1,430,989,125.43 in the previous period, indicating a growth of approximately 0.1%[38] - The total profit for the current period is approximately ¥579.55 million, a decrease from ¥666.50 million in the previous period, representing a decline of about 13.06%[39] - The net profit attributable to shareholders of the parent company is ¥442.05 million, down from ¥522.58 million, reflecting a decrease of approximately 15.38%[39] - Basic and diluted earnings per share are both ¥0.4950, down from ¥0.5852, reflecting a decrease of about 15.99%[39] Assets and Liabilities - The total assets at the end of Q3 2025 were ¥6,424,704,230.26, an increase of 6.53% from the end of the previous year[5] - Current assets totaled ¥3,930,608,517.36, up from ¥3,786,642,193.57, marking an increase of about 3.8%[34] - Non-current assets increased to ¥2,494,095,712.90 from ¥2,244,259,250.58, showing a growth of approximately 11.1%[35] - Total liabilities rose to ¥994,265,312.13 from ¥887,237,280.20, reflecting an increase of approximately 12.1%[35] - Shareholders' equity increased to ¥5,430,438,918.13 from ¥5,143,664,163.95, representing a growth of about 5.6%[36] Expenses - The company experienced a 9.75% increase in sales expenses year-over-year, impacting overall profitability[15] - Management expenses increased by 30.43% to ¥92,932,807.31, mainly due to a year-on-year increase in share-based payment expenses[21] - Financial expenses surged by 92.89% to ¥9,490,828.46, primarily due to a decrease in bank deposit interest income[21] - Total operating costs increased to ¥904,982,197.64 from ¥818,680,422.69, representing a rise of about 10.5%[38] - Research and development expenses for the current period were ¥33,003,853.59, compared to ¥30,458,497.52 in the previous period, indicating an increase of approximately 8.4%[38] Cash Flow - Operating cash inflows increased by 1.99% to ¥1,553,084,830.29, while operating cash outflows rose by 4.92% to ¥978,367,348.02[24] - The operating cash flow for the current period is ¥574.72 million, slightly down from ¥590.25 million, indicating a decrease of about 2.93%[41] - The total cash inflow from investment activities is ¥3.86 billion, compared to ¥2.46 billion in the previous period, showing an increase of approximately 56.73%[41] - The net cash flow from financing activities is -¥458.76 million, worsening from -¥282.54 million in the previous period, indicating a decline of about 62.38%[42] - Cash and cash equivalents at the end of the period were ¥773,689,250.75, up from ¥758,365,298.49, reflecting a growth of about 2.0%[34] - The cash and cash equivalents at the end of the period amount to ¥770.96 million, down from ¥923.77 million, indicating a decrease of approximately 16.46%[42] Shareholder Information - The total number of common shareholders at the end of the reporting period was 60,704[26] - The largest shareholder, Tao Yuequn, holds 33.35% of the shares, totaling 298,890,828 shares[26] - The top shareholder, Nanjing Otao Information Technology Co., Ltd., holds 100,464,421 shares, representing a significant portion of the company's equity[27] - The second-largest shareholder, Tao Yuequn, owns 74,722,707 shares, indicating a strong individual stake in the company[27] - The total number of shares held by the top 10 shareholders includes 15,241,012 shares from China Bank Co., Ltd. - Huabao CSI Medical ETF[27] - The company has a total of 224,168,121 restricted shares held by Tao Yuequn, which are subject to lock-up agreements[29] - The number of restricted shares for Fu Zhiying decreased by 25,000 shares, leaving a total of 358,352 shares under lock-up[29] - The company has not reported any changes in the top 10 shareholders due to margin trading activities[28] - There are no new restricted shares added during the reporting period, maintaining the current total[29] - The company has not disclosed any relationships or concerted actions among the top shareholders[27] - The total number of shares held by the top 10 unrestricted shareholders is 10,906,381 shares from the E Fund ChiNext ETF[27] - The company has not applied for any changes in the status of preferred shareholders or restricted shares[28] - The total number of shares for the company is 228,182,912, with 525,286 shares available for sale and 227,657,626 shares under lock-up[31] - The company has implemented various equity incentive plans with different lock-up periods ranging from 12 months to 60 months[30] - The total number of shares under other equity incentives is 2,794,887, with 373,786 shares available for sale[31] - The company has a total of 125,000 shares allocated for key personnel, with 100,000 shares under lock-up[30] - The company reported a significant number of shares under various incentive plans, indicating a strong commitment to employee retention and motivation[31] - The equity incentive plans are designed to incentivize performance and align with the company's long-term objectives[30] Market Strategy - The company is focusing on expanding its market presence and enhancing its product offerings through ongoing research and development initiatives[32] - The company is actively managing its share structure to optimize shareholder value and support future growth strategies[32] - The company is committed to transparency in its financial reporting and shareholder communications[32] Audit Information - The company has not undergone an audit for the third quarter financial report[43]

Core Viewpoint - The company, Opcon Vision, has received a new medical device production license from the Anhui Provincial Drug Administration, indicating an expansion in its production capabilities and product range [2]. Group 1: License Update - The company has completed the change registration for its medical device production license [2]. - The new license includes an additional production address located at "No. 1, 1st Floor, Building C, 4899 Wangjiang West Road, High-tech Zone, Hefei" [2]. - The production scope has been expanded to include "08-05 respiratory, anesthesia, and emergency device auxiliary equipment" [2].

欧普康视科技股份有限公司 关于医疗器械生产许可证变更的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 欧普康视科技股份有限公司（以下简称"公司"）于近日收到安徽省药品监 督管理局换发的《医疗器械生产许可证》（许可证编号：皖药监械生产许 20150064 号），完成了医疗器械生产许可变更登记。本次变更主要涉及生产地址增加"合 肥市高新区望江西路 4899 号 1#C 楼 1 层"和生产范围增加"08-05 呼吸、麻醉、 急救设备辅助装置"。具体情况如下： 一、《医疗器械生产许可证》基本情况 证券代码：300595 证券简称：欧普康视 公告编号：2025-083 8、许可期限：自 2025 年 10 月 9 日至 2030 年 7 月 23 日 9、发证部门：安徽省药品监督管理局 10、发证时间：2025 年 10 月 9 日 二、对公司的影响及风险提示 1、许可证编号：皖药监械生产许 20150064 号 2、统一社会信用代码：91340100723323559X 3、企业名称：欧普康视科技股份有限公司 4、法定代表人/企业负责人：陶悦群 5、住所：合肥市 ...

Group 1: Industry Overview - The medical device market in China is experiencing rapid growth, with the market size projected to increase from 440.3 billion yuan in 2017 to 1,154.4 billion yuan by 2024, representing a compound annual growth rate (CAGR) of 14.76%, significantly higher than the global CAGR of 4.82% during the same period [2] - By 2025, the market size is expected to reach 1.24 trillion yuan, and by 2030, it is anticipated to exceed 1.66 trillion yuan, driven by government support and increasing per capita medical spending [2] - The establishment of the Anhui Medical Device Innovation Alliance aims to enhance collaboration within the industry and promote the development of high-end medical imaging equipment [2] Group 2: Company Developments - Companies in the medical device sector are focusing on high-end product development, with significant investments in research and development [4] - Opcon Vision has successfully developed a high-permeability oxygen material, DK185, which exceeds industry standards, leading to the launch of new products such as corneal reshaping lenses [4] - Anhui Zhongke Ion Medical Technology Equipment Co., Ltd. has created China's first and the world's most compact superconducting proton therapy system, with a domestic production rate of over 95%, currently in clinical trial [4] - Anhui Tongling Bionic Technology Co., Ltd. has completed clinical trial enrollment for its "interventional ventricular assist system," which has been approved for expedited review by the National Medical Products Administration [5]

Core Viewpoint - The company has recently launched a new functional framework glasses called "Compound Control" aimed at myopia prevention, while maintaining a cautious approach towards children's eye monitoring glasses due to past experiences [1] Company Summary - The company is focusing on the development of eye care technologies rather than solely monitoring devices for children [1]

Core Insights - The company OPPLE Optoelectronics reported that as of October 10, 2025, the total number of shareholders is 61,458 [2] Company Summary - OPPLE Optoelectronics has engaged with investors through an interactive platform, providing updates on shareholder numbers [2] - The company is actively communicating with its investors, indicating a focus on transparency and shareholder engagement [2]

Core Viewpoint - Oupeng Vision reported that as of October 10, 2025, the total number of shareholders is 61,458 [2] Company Summary - Oupeng Vision has a total of 61,458 shareholders as of the specified date [2]

Core Viewpoint - The company OPPLE Optoelectronics will disclose its third-quarter report on October 25, providing insights into its operational performance [2] Summary by Categories - **Company Announcement** - OPPLE Optoelectronics will release its third-quarter financial report on October 25 [2] - Investors are encouraged to review the operational details in the upcoming report [2]

Core Insights - The company, Opcon Vision, is actively monitoring new technological developments related to vision health and conducts regular evaluations to identify suitable projects for timely initiation [2] Group 1 - The company is committed to tracking advancements in vision health technology [2] - Regular discussions and assessments are held to evaluate new technologies [2] - Suitable projects will be promptly initiated based on evaluations [2]